Welcome
Support Centre
21 May 2012 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
Prevention of catheter-related deep vein thrombosis with nadroparin in hemato-oncology patients treated with high dose chemotherapy
ISRCTN ISRCTN29686154
ClinicalTrials.gov identifier
Public title Prevention of catheter-related deep vein thrombosis with nadroparin in hemato-oncology patients treated with high dose chemotherapy
Scientific title
Acronym N/A
Serial number at source N/A
Study hypothesis Low dose nadroparin will prevent symptomatic and asymptomatic catheter-related deep vein thrombosis in patients treated with high dose chemotherapy.
Lay summary
Ethics approval Not provided at time of registration
Study design Randomized controlled trial
Countries of recruitment Netherlands
Disease/condition/study domain Hemato-oncology patients with deep vein thrombosis
Participants - inclusion criteria 1. Central venous catheter
2. Indication for high dose chemotherapy (acute myeloid leukaemia [AML], acute lymphoblastic leukaemia [ALL], myelodysplasia-refractory anemia with excess of blasts in transformation [MDS-RAEB], multiple mye!oma [MM])
3. Informed consent
Participants - exclusion criteria 1. Current anticoagulant therapy
2. Allergy for contrastmedia
3.Promyelocytic leukemia (AML-M3)
4. Bleeding tendency
5. Renal failure
Anticipated start date 10/04/2002
Anticipated end date 01/07/2006
Status of trial Completed
Patient information material
Target number of participants 100
Interventions Subcutaneous (SC) nadroparin 1 dd 2850 E versus subcutaneous placebo 0.3 ml for 21 days
Primary outcome measure(s) Asymptomatic and symptomatic catheter-related deep vein thrombosis proven by ultrasound or venography
Secondary outcome measure(s) 1. Catheter-related infections
2. Bleeding complications
Sources of funding Academic Medical Center (AMC)
Trial website
Publications
Contact name Dr  B.J.  Biemond
  Address Academic Medical Center (AMC)
Department of Clinical Chemistry
P.O. Box 22660
  City/town Amsterdam
  Zip/Postcode 1100 DD
  Country Netherlands
  Tel +31 (0)20 5667391
  Email b.j.biemond@amc.uva.nl
Sponsor Academic Medical Center (AMC) (The Netherlands)
  Address P.O. Box 22660
  City/town Amsterdam
  Zip/Postcode 1100 DD
  Country Netherlands
Date applied 09/06/2006
Last edited 09/06/2006
Date ISRCTN assigned 09/06/2006
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2012 ISRCTN unless otherwise stated.


BioMed Central